CN103097388A - 新的氨基吡唑并喹唑啉 - Google Patents

新的氨基吡唑并喹唑啉 Download PDF

Info

Publication number
CN103097388A
CN103097388A CN201180043930XA CN201180043930A CN103097388A CN 103097388 A CN103097388 A CN 103097388A CN 201180043930X A CN201180043930X A CN 201180043930XA CN 201180043930 A CN201180043930 A CN 201180043930A CN 103097388 A CN103097388 A CN 103097388A
Authority
CN
China
Prior art keywords
group
alkyl
yuan
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180043930XA
Other languages
English (en)
Chinese (zh)
Inventor
M·特鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103097388(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN103097388A publication Critical patent/CN103097388A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180043930XA 2010-07-23 2011-07-22 新的氨基吡唑并喹唑啉 Pending CN103097388A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10170683.6 2010-07-23
EP10170683 2010-07-23
PCT/EP2011/062683 WO2012010704A1 (en) 2010-07-23 2011-07-22 New aminopyrazoloquinazolines

Publications (1)

Publication Number Publication Date
CN103097388A true CN103097388A (zh) 2013-05-08

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180043930XA Pending CN103097388A (zh) 2010-07-23 2011-07-22 新的氨基吡唑并喹唑啉

Country Status (23)

Country Link
US (1) US8735386B2 (https=)
EP (1) EP2595987B1 (https=)
JP (1) JP5991974B2 (https=)
KR (1) KR20130132394A (https=)
CN (1) CN103097388A (https=)
AP (1) AP2012006640A0 (https=)
AR (1) AR082850A1 (https=)
AU (1) AU2011281504A1 (https=)
BR (1) BR112013000107A2 (https=)
CA (1) CA2803467A1 (https=)
CL (1) CL2012003745A1 (https=)
CO (1) CO6670575A2 (https=)
EA (1) EA201201661A1 (https=)
EC (1) ECSP13012448A (https=)
GE (1) GEP20156289B (https=)
MA (1) MA34389B1 (https=)
MX (1) MX2013000821A (https=)
PE (1) PE20131143A1 (https=)
PH (1) PH12013500152A1 (https=)
SG (1) SG187548A1 (https=)
TW (1) TW201217380A (https=)
UY (1) UY33526A (https=)
WO (1) WO2012010704A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383019A (zh) * 2017-07-28 2017-11-24 江苏艾凡生物医药有限公司 吡唑并[4,3‑h]喹唑啉类化合物及其用途
WO2018086591A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN108484600A (zh) * 2017-05-26 2018-09-04 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
CN113518775A (zh) * 2019-03-07 2021-10-19 生物技术公司 用于制备经取代的咪唑并喹啉的方法
CN113710225A (zh) * 2019-04-19 2021-11-26 范德生物公司 活性剂在皮肤内的递送和保留
WO2022166725A1 (zh) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
US12311048B2 (en) 2018-11-02 2025-05-27 Fount Bio, Inc. Crosslinked materials

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110585A1 (en) 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
HUE052821T2 (hu) 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
JP6664414B2 (ja) * 2015-05-13 2020-03-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＧＦ−１Ｒ／ＩＲ阻害薬としての新規５，８−ジメチル−９−フェニル−５，８−ジヒドロ−６Ｈ−ピラゾロ［３，４−ｈ］キナゾリン−２−イル）−（１Ｈ−ピラゾール−３−イル）−アミン及び誘導体
WO2019206154A1 (zh) 2018-04-24 2019-10-31 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12570670B2 (en) 2019-01-30 2026-03-10 Yale University Compounds, compositions, and methods for treating fibrosis
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198743A (zh) * 1995-10-02 1998-11-11 弗·哈夫曼-拉罗切有限公司 作为5HT2c－受体拮抗剂的嘧啶衍生物
WO2004104007A1 (en) * 2003-05-22 2004-12-02 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
WO2005037843A1 (en) * 2003-10-14 2005-04-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198743A (zh) * 1995-10-02 1998-11-11 弗·哈夫曼-拉罗切有限公司 作为5HT2c－受体拮抗剂的嘧啶衍生物
WO2004104007A1 (en) * 2003-05-22 2004-12-02 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
WO2005037843A1 (en) * 2003-10-14 2005-04-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264935A (zh) * 2016-11-11 2021-08-17 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物及其中间体和医药上的用途
WO2018086591A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN108699067A (zh) * 2016-11-11 2018-10-23 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
US11168088B2 (en) 2016-11-11 2021-11-09 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
CN108699067B (zh) * 2016-11-11 2021-06-15 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN108484600A (zh) * 2017-05-26 2018-09-04 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN108484600B (zh) * 2017-05-26 2022-12-13 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN107383019A (zh) * 2017-07-28 2017-11-24 江苏艾凡生物医药有限公司 吡唑并[4,3‑h]喹唑啉类化合物及其用途
US12311048B2 (en) 2018-11-02 2025-05-27 Fount Bio, Inc. Crosslinked materials
CN113518775A (zh) * 2019-03-07 2021-10-19 生物技术公司 用于制备经取代的咪唑并喹啉的方法
CN113710225A (zh) * 2019-04-19 2021-11-26 范德生物公司 活性剂在皮肤内的递送和保留
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
WO2022166725A1 (zh) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
CN116761806A (zh) * 2021-02-08 2023-09-15 南京明德新药研发有限公司 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
US12577253B2 (en) 2021-02-08 2026-03-17 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 5,6-dihydrothieno[3,4-h]quinazoline compound

Also Published As

Publication number Publication date
UY33526A (es) 2012-02-29
EA201201661A1 (ru) 2013-07-30
GEP20156289B (en) 2015-05-25
JP2013532652A (ja) 2013-08-19
CO6670575A2 (es) 2013-05-15
KR20130132394A (ko) 2013-12-04
CL2012003745A1 (es) 2013-05-31
MA34389B1 (fr) 2013-07-03
CA2803467A1 (en) 2012-01-26
EP2595987A1 (en) 2013-05-29
US20120238542A1 (en) 2012-09-20
PH12013500152A1 (en) 2013-02-18
SG187548A1 (en) 2013-03-28
AR082850A1 (es) 2013-01-16
AP2012006640A0 (en) 2012-12-31
WO2012010704A1 (en) 2012-01-26
ECSP13012448A (es) 2013-03-28
AU2011281504A1 (en) 2013-01-10
PE20131143A1 (es) 2013-10-23
US8735386B2 (en) 2014-05-27
BR112013000107A2 (pt) 2016-05-17
MX2013000821A (es) 2013-05-30
TW201217380A (en) 2012-05-01
JP5991974B2 (ja) 2016-09-14
EP2595987B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
JP5991974B2 (ja) 新規アミノピラゾロキナゾリン
EP2552905B1 (en) B-Raf kinase inhibitors
JP5809288B2 (ja) Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン
CN104870448B (zh) 三唑并吡嗪
US9428513B2 (en) Triazolopyrazine
JP5850952B2 (ja) セリン／スレオニンキナーゼ阻害剤としての新しいアザインドリルフェニルスルホンアミド
JP6128133B2 (ja) Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン
JP5863058B2 (ja) １Ｈ−イミダゾ［４，５−ｃ］キノリン
EP2552907B1 (en) Pyridyltriazoles
JP5824068B2 (ja) セリン／トレオニンキナーゼ阻害剤としての新規トリアゾリルフェニルスルホンアミド
JP6488367B2 (ja) ベンゾイミダゾール誘導体
JP2014503573A (ja) セリン／スレオニンキナーゼ阻害薬としての新規ピリミド［５，４−ｄ］ピリミジルアミノフェニルスルホンアミド
HK1180313A (en) New aminopyrazoloquinazolines
TW201307321A (zh) 新苯甲基羥吲哚嘧啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180313

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1180313

Country of ref document: HK